Surrozen, Inc. (SRZN) Q4 2022 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Surrozen, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.009 -- 00:00:04.491 Good afternoon and welcome to the Sarozen corporate update conference call. 00:00:04.491 -- 00:00:07.212 My name is Josh and I will be your manager for this call. 00:00:07.212 -- 00:00:14.174 I will now turn the call over to Craig Parker, CEO of Sarozen to begin the call. 00:00:14.915 -- 00:00:19.097 Thanks, Josh. And thank all of you for joining us today for this important corporate 00:00:19.097 -- 00:00:22.778 update. As Josh said, I'm Craig Parker, CEO of Sarozen. 00:00:22.778 -- 00:00:27.793 And with me today is Chuck Williams, the chief financial officer at Sarozen. 00:00:27.793 -- 00:00:32.935 We'll be providing corporate and R&D pipeline updates today, and we'll then address 00:00:32.935 -- 00:00:34.935 questions. 00:00:35.215 -- 00:00:37.536 Slide two. 00:00:38.436 -- 00:00:40.837 I'll be making forward-looking statements. 00:00:40.837 -- 00:00:44.879 Please consult our SEC filings, in particular 00:00:44.879 -- 00:00:51.240 our 2022 annual report on Form 10-K for a full discussion of our risk factors. 00:00:51.741 -- 00:00:54.081 Slide three. 00:00:54.648 -- 00:01:00.453 As some of you know, Surizin is the preeminent innovator in using the Wnt pathway, 00:01:00.453 -- 00:01:05.517 the body's own physiologic mechanism for tissue repair, to selectively 00:01:05.517 -- 00:01:10.320 stimulate tissue regeneration in a broad range of diseases. 00:01:10.320 -- 00:01:14.524 We do this through our proprietary platform and technologies 00:01:14.524 -- 00:01:19.568 that combine an understanding of Wnt pathway biology in specific disease 00:01:19.568 -- 00:01:26.447 settings with advanced antibody engineering techniques and proprietary antibody technologies. 00:01:26.447 -- 00:01:31.450 Our vision is to design and develop tissue-selec...